This has expired.
This Post-Activity Assessment contains 25 questions.
0 of 25 questions completed
You have already completed the assessment before. Hence you can not start it again.
Assessment is loading…
You must sign in or sign up to start the assessment.
You must first complete the following:
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
A minimum score of 70% is required to complete the evaluation and application for credit.
Among the advantages of T-CELL therapy is:
During the time between leukapheresis and the start of CAR T therapy, the patient is given chemotherapy to:
What are indicators of clinical success in CAR T cell therapy?
Which factor influences the next steps in treatment if a patient relapses after CAR T therapy?
What is the initial presenting sign of Cytokine Release Syndrome (CRS)?
Why do some ALL patients relapse within six months after CAR-T therapy?
If there are any significant signs of neurotoxicity after Cytokine Release Syndrome (CRS), the treatment of choice includes:
For all T-cell protocols, the cells must be sent fresh for production.
12 hours after T-cell transplant, what is the best treatment protocol for a Chronic Lymphocytic Leukemia (CLL) patient with a 102 degree temperature?
Which statement describing Multiple Myeloma is false?
For multiple myeloma patients, Anti-BCMA CAR T-cell therapy:
Financial factors that affect whether to seek CAR T for a patient include:
Hospitals are working on an arrangement with a manufacturer of T-cells so that they will only get a bill if there is a positive response in the patient at 30 days.
Insurance companies often have exclusions for investigational and experimental drugs even though they have been approved by the FDA.
How does neurotoxicity present in a patient treated with CAR T-cell therapy?
For pediatric patients, the most common mechanism for insurance reimbursement is:
What health-related characteristics would disqualify a patient from receiving CART T therapy?
The clinical syndrome of Cytokine Release Syndrome (CRS) can include all of the following, except:
Which characteristic does not reflect the profile of a patient who will receive CAR T therapy?
How long does it take for T-cell infusion?
Which characteristic is not a side effect of post-CAR T infusion?
Severe CRS after CAR T cell therapy can be an indication that:
CAR T cell products have not been approved for:
During the treatment of CRS, when is it appropriate to add steroids?
What are some of the important psychosocial factors to consider before starting CAR T therapy?